C15:0 and Healthy Aging: Interesting Science, Limited Human Evidence
C15:0 has a good origin story. It is an unusual fatty acid, the research behind it grew in part out of work involving dolphins in the U.S. Navy Marine Mammal Program, and laboratory studies have identified several biological effects that could plausibly be relevant to aging. It is now sold as a healthy-aging supplement, most visibly under the Fatty15 brand.
The advertising has moved considerably faster than the human evidence.
Clinical Overview: C15:0, or pentadecanoic acid, is an odd-chain saturated fatty acid found naturally in dairy fat and some other foods. Higher circulating levels have been associated with better metabolic health in observational studies, and laboratory research suggests potentially useful effects involving cell membranes, mitochondria and several pathways connected to aging biology.
Human supplementation data remain limited. A small 12-week randomized trial showed that taking C15:0 raises circulating C15:0 and appears reasonably well tolerated. Another randomized trial found some additional LDL lowering when C15:0 was added to a Mediterranean-style diet, although the dietary intervention itself produced most of the improvement in liver fat, weight and metabolic measures.
At HormoneSynergy®, we would not put C15:0 ahead of Mediterranean-style nutrition, extra-virgin olive oil, fatty fish, appropriately selected omega-3 therapy, adequate protein, resistance training or creatine. C15:0 is interesting enough to follow. It is not yet a foundational longevity intervention.
Why C15:0 Has Attracted So Much Attention
Pentadecanoic acid is a 15-carbon saturated fatty acid. Because it has an odd number of carbon atoms, it behaves differently from more familiar even-chain saturated fatty acids such as palmitic acid.
Researchers have reported associations between higher circulating C15:0 and lower rates of diabetes and some cardiometabolic risk factors. Experimental studies have also explored effects involving mitochondrial function, cell-membrane stability, inflammatory signaling and ferroptosis.
Those findings provide a reason to study C15:0. They do not establish that taking a C15:0 capsule slows aging in people.
The claim that C15:0 should be considered a newly discovered essential fatty acid also remains unsettled. Current nutritional guidance recognizes alpha-linolenic acid and linoleic acid as essential fatty acids. There is no established Dietary Reference Intake for C15:0 and no generally accepted human C15:0 deficiency syndrome.
Calling it a promising nutrient is reasonable. Calling it a required longevity nutrient is premature.
What the Human Trials Actually Found
The first randomized human supplementation trial included only 30 young adults with overweight or obesity. Twenty received 200 mg of C15:0 daily and ten received placebo for 12 weeks.
C15:0 supplementation did what it was expected to do: circulating C15:0 increased. The supplement was generally well tolerated, and exploratory analyses produced several potentially favorable findings involving liver enzymes and other biomarkers. The trial was far too small and short to tell us whether supplementation prevents cardiovascular disease, diabetes, dementia or other age-related disease.
Read the randomized C15:0 supplementation trial on PubMed.
The TANGO randomized trial provides another useful perspective. Eighty-eight women with fatty liver disease were assigned to an Asian-adapted Mediterranean diet with C15:0, the same dietary intervention without C15:0, or a control diet.
Liver fat fell by roughly 33% with the Mediterranean-style diet plus C15:0 and about 30% with the diet alone. Both Mediterranean-diet groups also improved weight, triglycerides and several metabolic measures. Adding C15:0 produced a greater reduction in LDL cholesterol.
That is a favorable result for C15:0, but the larger effect came from changing the diet. The difference in liver-fat reduction between the two Mediterranean-diet groups was modest.
Read the TANGO randomized trial on PubMed.
A 2026 analysis from the CARDIA and ARIC cohorts adds some needed caution. Higher circulating C15:0 was associated with slightly lower blood pressure and a lower observed risk of developing hypertension. Researchers found no significant association with incident cardiovascular disease, however, and genetic analyses did not support a causal cardiovascular benefit from higher C15:0.
Some of the favorable C15:0 associations may therefore reflect the health or dietary patterns of people who have higher levels rather than a direct protective effect of the fatty acid itself.
Read the 2026 CARDIA/ARIC analysis on PubMed.
How C15:0 Compares With What We Already Have
Novelty is not a useful way to rank longevity interventions. We are more interested in how much human evidence exists and whether an intervention has improved outcomes that patients actually care about.
| Intervention | What we know | Current HS priority |
|---|---|---|
| Mediterranean-style nutrition + extra-virgin olive oil | Large human trials, including cardiovascular outcome data. | Foundational |
| EPA/DHA | Decades of human research. Benefits depend on diet, formulation, dose and clinical indication. | Food first; individualized supplementation or prescription therapy |
| Resistance training + creatine | Substantial human evidence for strength and preservation of lean tissue, particularly with resistance exercise. | High priority for healthy aging |
| C15:0 | Interesting mechanistic and observational research with limited randomized human supplementation data. | Promising, not foundational |
Extra-virgin olive oil is an especially useful comparison. The PREDIMED trial involved thousands of adults at elevated cardiovascular risk and demonstrated fewer major cardiovascular events with Mediterranean dietary patterns supplemented with extra-virgin olive oil or nuts.
Read the PREDIMED trial on PubMed.
Omega-3 fatty acids also have a much deeper human evidence base, although we do not recommend routine high-dose fish oil simply because someone wants to live longer. Fatty fish is a valuable part of a Mediterranean-style diet. Supplemental EPA and DHA should be considered in the context of diet, triglycerides, cardiovascular risk and the reason for treatment.
Prescription icosapent ethyl is a separate issue from ordinary over-the-counter fish oil. In REDUCE-IT, purified EPA reduced cardiovascular events in selected statin-treated patients with elevated triglycerides and substantial cardiovascular risk. Other omega-3 trials have produced different results, and higher-dose therapy can increase atrial fibrillation risk in susceptible patients.
Read the REDUCE-IT trial on PubMed.
Creatine is not a fatty acid, but it belongs in this comparison because patients have limited money, time and attention. For an aging adult, preserving muscle has immediate relevance to glucose metabolism, mobility, bone loading, recovery from illness and physical independence. Creatine combined with resistance training has considerably more human evidence behind it than C15:0 currently does.
Review recent evidence on creatine and resistance training in older adults.
Where HormoneSynergy® Would Put C15:0 Today
We would not tell a patient who is already taking C15:0 that the supplement is worthless. The science is interesting enough to justify further research, and the available short-term human data have not raised an obvious safety signal.
We also would not move it ahead of interventions with substantially stronger evidence.
For most of our patients, we would first address Mediterranean-style nutrition, protein intake, resistance exercise, body composition, visceral fat, blood pressure, apoB, Lp(a), glucose and insulin resistance, sleep, smoking and other established determinants of healthspan. Fatty fish, extra-virgin olive oil and creatine have clear roles within that larger strategy. Omega-3 supplementation or prescription EPA may have a role when the patient's clinical picture supports it.
A person who has already addressed those priorities and wants to try C15:0 is making a different decision. At that point it can be viewed as an emerging nutrient with interesting early evidence rather than a substitute for proven care.
We would not currently diagnose a C15:0 deficiency simply because a commercial test reports a low level. We would not replace clinically indicated omega-3 therapy with C15:0. And we would not tell someone that taking C15:0 has been shown to slow biological aging.
The research has not demonstrated that.
Our current position: C15:0 is worth watching and reasonable to study. It has not earned a foundational place in longevity medicine.
Related HormoneSynergy® Resources
- HormoneSynergy® Longevity Medicine Resource Library
- DEXA Bone Density & Body Composition Testing
- Cleerly® CCTA Heart Plaque Testing
Editorial Transparency
This article is educational and reflects the HormoneSynergy® approach to preventive longevity medicine. C15:0 is discussed in the context of published human research and compared with interventions that currently have a larger clinical evidence base. Commercial claims should not be interpreted as established clinical outcomes unless they have been demonstrated in appropriate human trials.
Selected Clinical Resources
Robinson MK, et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of Nutrition. 2024.
PubMed
Chooi YC, et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. American Journal of Clinical Nutrition. 2024.
PubMed
Steffen BT, et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in Nutrition. 2026.
PubMed
Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019.
PubMed
Estruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. New England Journal of Medicine. 2018.
PubMed
National Institutes of Health Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals.
NIH Office of Dietary Supplements
Frequently Asked Questions
Has C15:0 been shown to slow biological aging?
No. Laboratory studies have identified effects involving biological pathways associated with aging, but human trials have not demonstrated that C15:0 supplementation slows biological aging, extends lifespan or prevents age-related disease.
Is C15:0 better than omega-3 fatty acids?
There is currently no evidence showing that it is. EPA and DHA have a much larger human evidence base. The appropriate use of omega-3s still depends on diet, dose, formulation and the patient's cardiovascular and metabolic risk.
Would HormoneSynergy® recommend C15:0?
We currently consider C15:0 an optional emerging nutrient rather than a foundational longevity supplement. We would first address nutrition, exercise, muscle preservation, cardiovascular risk, metabolic health and other interventions with substantially stronger human evidence.
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →